Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Biotechnology

Healthcare
$9.24 -3.20%

-$0.39 today

Market cap
$326.66M
Beta
0.89
P/E (TTM)
-7.5
EPS (TTM)
-$1.57
52W Low $3.69High $16.33

Volume 0.20M

Average 0.26M

CTNM EPS (Diluted)

Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.

Contineum Therapeutics, Inc. Class A Common StockNASDAQ: CTNM

EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026

EPS (Diluted) remains negative

Q1 FY2026 EPS (Diluted) was -$0.39, compared with -$0.62 a year earlier. Trailing-twelve-month EPS (Diluted) was -$1.95.

Context

  • EPS (Diluted) increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Diluted) reaches the consensus estimate from 5 analysts of -$1.79 (+17.7%) for the fiscal year ending Dec 2026, a step up from the -33.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.39+20.4% QoQ
Last fiscal yearDec 2025
-$2.17-33.1% YoY
LTMMar 2026
-$1.95-1.0% YoY
EPS (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.1%+27.6%-9.5 pp
1 year-33.1%+17.7%+50.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Diluted) history

USD · from the income statement

Latest · FY2025
(2.17) USD
Year-over-year change
-33.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Diluted) vs competitors

How CTNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -1.0% is the 2nd highest of 7, against a peer median of -16.0%.
CTNM Competitors
EPS (Diluted) for CTNM and competitors
Company Period LTM YoY 3-year CAGR
ACIUAC Immune S.A.LTM Mar 2026-CHF 0.66 CHF-26.9%—
GHRSGH Research PLCLTM Mar 2026-$0.92 USD-16.5%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$1.33 USD+17.4%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$1.95 USD-1.0%—
ANROAlto Neuroscience, Inc.LTM Mar 2026-$2.48 USD-6.4%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-$2.6 USD-15.6%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026-$4.58 USD-134.9%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026-$21.47 USD——
SPTXSeaport Therapeutics, Inc. Common Stock—— ——
Peer median (excluding CTNM) —-16.0%—

Competitors are the stored peer set for CTNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0050M00
Cost of Revenue000258K0
Gross Profit0050M(258K)0
Gross Margin——100.0%——
Research & Development22.36M16.89M27.6M38.16M51.52M
Selling, General & Admin6.29M5.83M6.32M12.47M16.54M
Operating Expenses28.65M22.72M66.08M50.64M68.06M
Depreciation & Amortization325K329K195K258K323K
EBITDA(28.34M)(23.54M)23.57M(42M)(59.66M)
EBITDA Margin——47.1%——
Operating Income(28.65M)(22.72M)(16.08M)(50.89M)(68.06M)
Operating Margin——-32.2%——
Interest Income77K761K4.61M8.91M8.25M
Interest Expense332K388K208K00
Other Income / Expenses(354K)(1.53M)39.25M8.64M8.08M
Income Before Tax(29M)(24.25M)23.17M(42.26M)(59.98M)
Pre-Tax Margin——46.3%——
Income Tax Expense00450K00
Net Income(29M)(24.25M)22.72M(42.26M)(59.98M)
Net Margin——45.4%——
EPS (Basic)(1.15)(0.97)0.13(1.63)(2.17)
EPS (Diluted)(1.15)(0.97)0.13(1.63)(2.17)
Weighted Avg Shares25.13M25.13M25.13M25.85M27.7M
Weighted Avg Shares (Diluted)25.13M25.13M25.13M25.85M27.7M

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Intrinsic Alpha fair value

Locked

Current Price

$9.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.